| 1.58 -0.09 (-5.39%) | 10-06 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.75 |
1-year : | 3.31 |
| Resists | First : | 2.35 |
Second : | 2.83 |
| Pivot price | 1.74 |
|||
| Supports | First : | 1.58 |
Second : | 1.31 |
| MAs | MA(5) : | 1.64 |
MA(20) : | 1.84 |
| MA(100) : | 2.25 |
MA(250) : | 4.77 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 4.6 |
D(3) : | 5.5  |
| RSI | RSI(14): 29.1 |
|||
| 52-week | High : | 24.89 | Low : | 1.51 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ INBS ] has closed above bottom band by 16.9%. Bollinger Bands are 51.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 2 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.81 - 1.82 | 1.82 - 1.83 |
| Low: | 1.56 - 1.57 | 1.57 - 1.58 |
| Close: | 1.56 - 1.58 | 1.58 - 1.59 |
Intelligent Bio Solutions Inc. operates as a life sciences firm focused on developing non-invasive, real-time monitoring and diagnostic solutions for both patients and their primary healthcare providers. A notable product in its portfolio is the Saliva Glucose Biosensor, an organic thin-film transistor designed to precisely measure glucose levels in saliva for effective diabetes management. Beyond this, the company is actively developing a SARS-CoV-2 Biosensor, intended to serve as a supplementary diagnostic tool to existing RNA virus detection methods. It also maintains a broad biosensor platform that encompasses diverse diagnostic modalities, including biochemistry, immunology, tumor marker identification, hormone analysis, and nucleic acid diagnostics. Incorporated in 2016 and based in New York, New York, the company was formerly known as GBS Inc. before adopting its current name in October 2022. Intelligent Bio Solutions Inc. operates as a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.
Thu, 24 Sep 2026
INTELLIGENT BIO SOLUTIONS INC. SEC Filing (Sep 24, 2026) | INBS EFFECT - Stock Titan
Thu, 10 Sep 2026
A fingerprint drug test company will discuss its FDA submission Sept. 24 - Stock Titan
Wed, 09 Sep 2026
Intelligent Bio Submits Comprehensive Clinical Data to Enter US Drug Screening Market - Yahoo Finance
Wed, 19 Aug 2026
Intelligent Bio Solutions Inc. Reports Earnings Results for the Full Year Ended June 30, 2026 - www.marketscreener.com
Tue, 21 Jul 2026
Intelligent Bio Solutions completes precision testing for FDA filing - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 3 (M) |
| Shares Float | 3 (M) |
| Held by Insiders | 2.9 (%) |
| Held by Institutions | 5.9 (%) |
| Shares Short | 105 (K) |
| Shares Short P.Month | 103 (K) |
| EPS | -8.44 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.89 |
| Profit Margin | -295 % |
| Operating Margin | -346 % |
| Return on Assets (ttm) | -76.2 % |
| Return on Equity (ttm) | -307.7 % |
| Qtrly Rev. Growth | 35.7 % |
| Gross Profit (p.s.) | 0.67 |
| Sales Per Share | 1.39 |
| EBITDA (p.s.) | -3.68 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -12 (M) |
| Levered Free Cash Flow | -7 (M) |
| PE Ratio | -0.19 |
| PEG Ratio | 0 |
| Price to Book value | 0.83 |
| Price to Sales | 1.13 |
| Price to Cash Flow | -0.41 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|